Hiramoto R, Ghanta V, Durant J R
Cancer Res. 1975 May;35(5):1309-13.
Data are presented on the response rates, maximum rate of cell kill, and survival rates for individual and groups of mice with MOPC 104E myeloma treated with a variety of chemotherapeutic agents and combination regimens used in clinical human myeloma. The tumor immunoglobulin M measurements are used to evalutae the therapeutic effects of drugs. Prednisolone and mescaline, when given as single drugs, showed no therapeutic action and the animals died of tumor as in the controls. The immunoglobulin M values are very similar and ranged between 8,125 and 13,410 mug/mouse. Prednisolone and melphalan given in combination indicated therapeutic effect. 1,3-Bis(2-chloroethyl)-1-nitrosourea-cyclophosphamide-prednisolone combination caused tumor regression but was toxic as shown by the immunoglobulin M values and percentage of survival. The complications and potential uses of this system, which utilized only 40 animals in 64 days, are discussed.
文中给出了用多种临床治疗人类骨髓瘤时使用的化疗药物及联合治疗方案治疗携带MOPC 104E骨髓瘤的个体小鼠和小鼠组的缓解率、最大细胞杀伤率及生存率的数据。肿瘤免疫球蛋白M测量值用于评估药物的治疗效果。单独使用泼尼松龙和三甲氧苯乙胺时无治疗作用,动物如对照组一样死于肿瘤。免疫球蛋白M值非常相似,范围在8,125至13,410微克/小鼠之间。联合使用泼尼松龙和美法仑显示出治疗效果。1,3 - 双(2 - 氯乙基)-1 - 亚硝基脲 - 环磷酰胺 - 泼尼松龙联合用药导致肿瘤消退,但从免疫球蛋白M值和生存率来看有毒性。讨论了该系统在仅64天内使用40只动物的情况下的并发症及潜在用途。